Tag

Your search for DAA returned 33 results.


HCV DAAs and Severe Renal Impairment

New report provides vital information needed by clinicians to treat HCV in patients with severe renal impairment with the approved DAAs simeprevir and sofosbuvir. Available clinical information on the use of sofosbuvir in patients with severe renal impairment is minimal, and there are currently no approved direct acting antiviral (DAA) treatments in this popula...

Read More


Interventions in the HCV care continuum

New systematic review in the journal International Journal of Drug Policy discusses published evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum. Authors note that primary care settings represent key opportunities for HCV care linkage interventions, often within clinics that have prolonged engagement ...

Read More


Hepatitis C RAVs are Not a Barrier to Retreatment

Study published in the journal Hepatology suggests that sofosbuvir plus peginterferon and ribavirin for 12 weeks is effective and safe in patients who have not achieved SVR with prior regimens of one or more direct-acting antiviral (DAA) agents plus peginterferon and ribavirin. High rates of SVR12 are achieved regardless of the presence of resistance associated ...

Read More


Dr. E Lebovics: Post-EASL 2015 HCV Interview

During our last interview, you mentioned that extending the use of all oral, interferon-free, hepatitis C regimens to special populations including those with decompensated cirrhosis, post-transplant, and renal failure is an area of great interest. We would like to hear your thoughts on relevant clinical data presented at The International Liver Congress™ 2015, ...

Read More


Barriers to Accessing HCV Therapies in the US

Recent study indicates that newly available, interferon-free HCV therapies will significantly increase access to care for HCV infected individuals in the US, as unlike standard interferon-based therapies, interferon-free therapies are associated with minimal contraindications. However, a large proportion of US individuals with chronic hepatitis C infection ...

Read More


Pooled safety data: ledipasvir/sofosbuvir: HCV-1

Pooled analysis of safety data from the three multicenter, randomized, open-label ION Phase 3 clinical trials shows that the addition of ribavirin to ledipasvir/sofosbuvir HCV-1 treatment regimens increased toxicity without providing additional efficacy. Eliminating ribavirin from HCV therapy will likely increase patient adherence to treatment due to an improved ...

Read More


Largest DAA study to date in HCV genotype 4

Largest study to date shows that the two direct-acting antiviral drug-only regimen (ombitasvir plus paritaprevir) is effective and well tolerated in both treatment-naive and treatment-experienced patients with HCV genotype 4 infection without cirrhosis. Note that patients also received low-dose ritonavir to increase paritaprevir peak and trough concentrations and ...

Read More


Special Interview on HCV: Dr. S. Wiktor of WHO

Thank you for agreeing to participate in this special interview on HCV. What do you see as the biggest global challenges in the diagnosis, screening, and treatment of hepatitis C? Dr. Wiktor: The landscape is changing very quickly and it is being driven by remarkable progress in the development of direct-acting antiviral therapies for hepatitis C. We hear ...

Read More


DAA HCV Regimen effective in pts with cirrhosis

Interferon free, direct acting antiviral HCV regimen ledipasvir-sofosbuvir with and without ribavirin is effective and well tolerated in adult patients with HCV genotype 1 and cirrhosis who have failed previous HCV therapy Chronically infected patients with cirrhosis, especially those who have failed previous hepatitis C therapy, achieve consistently lower rates ...

Read More


Treating hepatitis C in difficult-to-treat patients

Interferon-free treatment regimens are highly effective, well-tolerated, and enable clinicians to treat patients with hepatitis C who cannot be treated with interferon-based regimens. In a review article recently published in the journal Nature Reviews Gastroenterology & Hepatology, Peter Ferenci, MD, describes and assesses the application of interferon-free ...

Read More